Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial

Česká verzia

Authors: Eva Tůmová; Michal Vrablík
Authors place of work: III. interni klinika – endokrinologie a metabolismu, 1. LF UK a VFN v Praze
Published in the journal: AtheroRev 2023; 8(2): 85-94
Category: Reviews

Summary

Despite huge global efforts to reduce the incidence of cardiovascular disease (CVD), it is still the dominant cause of morbidity and mortality in the developed world. In recent years, there has been a significant reduction in the prevalence of CVDs due to the impact of major risk factors on primary and secondary prevention, especially the consistent treatment of arterial hypertension and dyslipidemia. However, despite the remarkable effect of statins, we are still not able to achieve the recommended target serum lipid levels in up to two-thirds of patients, which is why efforts to intensify hypolipidemic treatment are ongoing. Bempedoic acid, an ATP-citrate lyase inhibitor, represents a novelty among hypolipidemics. By limiting endogenous cholesterol synthesis, it reduces LDL-cholesterol levels and consequently the incidence of cardiovascular events. This new treatment is promising both as monotherapy in statin-intolerant patients (in whom it can achieve up to 40% reduction in LDL-cholesterol concentration) and as part of combination regimens. The following text summarises the current knowledge on the effects and safety of bempedoic acid and, in the light of the new findings and expert guidelines, provides practical recommendations on when the therapy should be indicated.

Keywords:

ATP-citrate lyase inhibitor – atherosclerosis – cardiovascular disease – bempedoic acid

Zdroje

1. Roth GA, Mensah GA, Johnson CO et al. [GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group]. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol 2020; 76(25): 2982–3021. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.11.010>.

2. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459–2472. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ ehx144>.

3. Jóźwiak JJ, Studziński K, Tomasik T et al. [LIPIDOGRAM2015 Investigators]. The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atheroscler Suppl 2020; 42:e15-e24. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosissup.2021.01.004>.

4. Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med 2020; 18(1): 320. Dostupné z DOI: <http://dx.doi. org/10.1186/s12916–020–01792–7>.

5. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532–2561. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(16)31357–5>.

6. Hobbs FD, Banach M, Mikhailidis DP et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med. 2016; 14: 4.10. Dostupné z DOI: <http:// dx.doi.org/1186/s12916–016–0550–5>.

7. Ray KK, Molemans B, Schoonen WM et al. [DA VINCI study]. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2021; 28(11): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/ zwaa047>.

8. Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.

9. Bytyci I, Penson PE, Mikhailidis DP et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022; 43(34): 3213–3223. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehac015.>.

10. Banach M, Penson PE. Lipid-lowering therapies: Better together. Atherosclerosis 2021; 320: 86–88. Dostupné z DOI: <http://dx.doi.org/ 10.1016/j.atherosclerosis.2021.01.009>.

11. Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res 2019; 115(3): e26-e31. Dostupné z DOI: <http://dx.doi. org/10.1093/cvr/cvy301>.

12. Henney NC, Banach M, Penson PE. RNA Silencing in the Management of Dyslipidemias. Curr Atheroscler Rep 2021; 23(11): 69. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–021–00968–7>.

13. Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs 2017; 26(2): 251– 259. Dostupné z DOI: <http://dx.doi.org/10.1080/13543784.2017.128045 8>.

14. Pinkosky SL, Newton RS, Day EA et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457. Dostupné z DOI: <http://dx.doi. org/10.1038/ncomms13457>.

15. Ballantyne CM, Davidson MH, Macdougall DE et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013; 62(13): 1154–62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.05.050>.

16. Thompson PD, Rubino J, Janik MJ et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol 2015; 9(3): 295–304. Dostupné z DOI: <http://dx.doi.org/10.1016/j. jacl.2015.03.003>.

17. Cicero AFG, Fogacci F, Hernandez AV et al. Lipid, Blood Pressure Meta- Analysis Collaboration G, the International Lipid Expert P. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Med 2020;17(7): e1003121. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pmed.1003121>.

18. Banach M, Duell PB, Gotto AM Jr et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol 2020; 5(10): 1124–1135. Dostupné z DOI: <http://doi 10.1001/jamacardio.2020.2314>.

19. Gunn LH, McKay AJ, Feng et al. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atheroscler Plus 2022; 49: 20–27. Dostupné z DOI: <http://dx.doi.org/ 10.1016/j.athplu.2022.05.003>.

20. Lin Y, Parco C, Karathanos A et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open 2022; 12(2): e048893. Dostupné z DOI: <http://dx.doi.org/10.1136/ bmjopen-2021–048893>.

21. Nicholls S, Lincoff AM, Bays HE et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2021; 235: 104–112. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2020.10.060>.

22. Esperion Therapeutics Inc. Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint. Dostupné z WWW: <https://www.aspconline.org/uncategorized/esperion- -announces-clear-cardiovascular-outcomes-trial-of-nexletol-bempedoic- -acid-meets-primary-endpoint/>.

23. Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388(15): 1353–1364. Dostupné z DOI: <http://dx.doi.org/10.1056/ NEJMoa2215024>.

24. Bays HE, Banach M, Catapano AL et al. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol 2020; 14(5): 649– 659 e6. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2020.08.009>.

25. Nilemdo 180 mg film-coated tablets. SPC. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/ nilemdo-epar-product-information_en.pdf>.

26. Banach M, Penson PE. Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia. Eur J Prev Cardiol 2022; 29(5): 718–720. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwaa145>.

27. Lewek J, Konopka A, Starostecka E et al. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. J Clin Med 2021; 10(19): 4302. Dostupné z DOI: <http://dx.doi.org/10.3390/jcm10194302>.

28. Banach M, Penson PE. Genetic testing in familial hypercholesterolaemia: What does it add? Eur J Prev Cardiol 2020; 27(1): 105–106. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487319870342>.

29. Banach M, Penson PE. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition. Eur J Prev Cardiol 2022; 29(5): 815–816. Dostupné z DOI: . <http://dx.doi.org/10.1093/eurjpc/ zwac032>.

30. Ray KK, Bays HE, Catapano AL et al. CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380(11): 1022–1032. Dostupné z DOI: <http://dx.doi.org/10.1056/ NEJMoa1803917>.

31. Ballantyne CM, Banach M, Bays HE et al. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol 2022; 174: 1–11. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2022.03.020>.

32. Penson PE, Bruckert E, Marais D et al. [International Lipid Expert Panel]. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle 2022; 13(3): 1596–1622. Dostupné z DOI: <http://dx.doi.org/10.1002/ jcsm.12960>.

33. Penson PE, Banach M. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. Eur Heart J 2021; 42(47): 4787– 4788. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab358.

34. Laufs U, Ballantyne CM, Banach M et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol 2022; 16(3): 286–297. Dostupné z DOI: <http://dx.doi.org/10.1016/j. jacl.2022.03.001>.

35. Laufs U, Banach M, Mancini GBJ et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc 2019; 8(7): e011662. Dostupné z DOI: <http://dx.doi. org/10.1161/JAHA.118.011662>.

36. Ballantyne CM, Banach M, Mancini GB et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018; 277: 195–203. Dostupné z DOI: <http://dx.doi.org/10.1016/j. atherosclerosis.2018.06.002>.

37. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340(2): 115–126. Dostupné z DOI: <http://dx.doi.org/10.1056/ NEJM199901143400207>.

38. Penson PE, Long DL, Howard G et al. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. Eur Heart J 2018; 39(40): 3641–3653. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ ehy533>.

39. Ridker PM, Everett BM, Thuren T et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377(12): 1119–1131. Dostupné z DOI: <http://dx.doi. org/10.1056/NEJMoa1707914>.

40. Bytyci I, Bajraktari G, Penson PE et al. [Lipid and Blood Pressure Meta- Analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP)]. Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2022; 88(4): 1520–1528. Dostupné z DOI: <http://dx.doi.org/10.1111/bcp.15041>.

41. Stroes ESG, Bays HE, Banach M et al. Bempedoic acid lowers high- -sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. Atherosclerosis 2023; 373: 1–9. Dostupné z DOI: <http://dx.doi.org/10.1016/j. atherosclerosis.2023.03.020>.

42. Pinkosky SL, Newton RS, Day EA et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457. Dostupné z DOI: <http://dx.doi. org/10.1038/ncomms13457>.

43. Maierean S, Webb R, Banach M et al. The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. Eur Heart J Open 2022; 2(4): oeac039. Dostupné z DOI: <http://dx.doi. org/10.1093/ehjopen/oeac039>.

44. Masson W, Lobo M, Lavalle-Cobo A et al. Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis. Diabetes Res Clin Pract 2020; 168: 108369. Dostupné z DOI: <http://dx.doi.oeg/10.1016/j. diabres.2020.108369>.

45. Leiter LA, Banach M, Catapano AL et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab 2022; 24(5): 868–880. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14645>.

46. Banach M, Surma S, Reiner Z et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol 2022; 21(1): Dostupné z DOI: <http://dx.doi. org/263.10.1186/s12933–022–01684–5>.